Literature DB >> 17395730

Vaccines against Francisella tularensis.

J Wayne Conlan1, Petra C F Oyston.   

Abstract

Francisella tularensis is one of the most pathogenic pathogens known, especially when disseminated as a small particle aerosol. Because of this, it was developed into a biological warfare agent by several states during the 20th century. Nowadays, concerns remain about the potential of this pathogen to cause widespread disease, tularemia, in the hands of terrorists. This has resurrected interest in methods to combat it. This article reviews the current status of vaccine development efforts against tularemia. To date most of our understanding of tularemia vaccine efficacy has been derived from the clinical and experimental use of a pragmatically attenuated live vaccine strain of F. tularensis subspecies holarctica. However, this vaccine which has been in existence for more than 50 years is still beset by regulatory issues that continue to hamper its licensure. These issues and possible solutions are highlighted, along with more modern molecular approaches to vaccine development against this highly virulent pathogen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395730     DOI: 10.1196/annals.1409.012

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  55 in total

1.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.

Authors:  H M El Sahly; R L Atmar; S M Patel; J M Wells; T Cate; M Ho; K Guo; M F Pasetti; D E Lewis; M B Sztein; W A Keitel
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

4.  A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.

Authors:  Qingmei Jia; Richard Bowen; Jacob Sahakian; Barbara Jane Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

5.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

6.  Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis.

Authors:  Kjell Eneslätt; Cecilia Rietz; Patrik Rydén; Svenja Stöven; Robert V House; Lawrence A Wolfraim; Arne Tärnvik; Anders Sjöstedt
Journal:  Eur J Immunol       Date:  2011-02-21       Impact factor: 5.532

7.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

8.  Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).

Authors:  Susan M Twine; Mireille D Petit; Kelly M Fulton; Robert V House; J Wayne Conlan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

Review 9.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

10.  Epitope-based vaccination against pneumonic tularemia.

Authors:  Stephen H Gregory; Stephanie Mott; Jennifer Phung; Jinhee Lee; Leonard Moise; Julie A McMurry; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.